An update on recent patents on thrombin inhibitors (2010 – 2013)

  title={An update on recent patents on thrombin inhibitors (2010 – 2013)},
  author={Akul Y. Mehta and Yingzi Jin and Umesh R. Desai},
  journal={Expert Opinion on Therapeutic Patents},
  pages={47 - 67}
Introduction: Thromboembolic incidences have increased nearly 33% in the past decade and directly affect nearly 0.5% of the population. Heparin, warfarin and current direct thrombin inhibitors (DTIs), the primary anticoagulants of choice, suffer from several drawbacks. Thus, the search for an antithrombotic devoid of adverse effect continues in earnest. Areas covered: Literature search covering PubMed, SciFinder™ Scholar, Web of Knowledge, Espacenet, PatentScope and Google Patent Search was… 
Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245
These pharmaceutically acceptable prodrugs where N-alkoxycarbonyl is protected or carboxylic acid is protected by ester could achieve prolonged half-life for a convenient once- or twice-daily oral dosing and gave a new hope and confidence to treat thrombotic disorders with selective and orally active thrombin inhibitors.
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases
This review summarizes the development of orally active thrombin inhibitors for the treatment of thrombotic disorder diseases, which could serve as a reference for the interested researchers.
Enzymatic and chemical synthesis of new anticoagulant peptides
The results suggest that two new anticoagulant peptides (Z‐YQQ and YQQ) can be useful for safe pharmaceutical applications, Nevertheless, some aspects related to peptide production should be optimized.
Pathophysiological significance and therapeutic applications of snake venom protease inhibitors
Antithrombotic Activity of Milk Protein Hydrolysates by Lactic Acid Bacteria Isolated from Commercial Fermented Milks
In the last decade, thrombosis has been one of the pathologies with high incidence creating great concern in Health Institutes all around the world. Considering this, the aim of this research was to
Rapid magnetic solid-phase extraction combined with ultra-high performance liquid chromatography and quadrupole-time-of-flight mass spectrometry for analysis of thrombin binders from a crude extract and injection of Erigeron breviscapus
Thrombin, which acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, plays crucial roles in the blood coagulation pathway. Inhibition of thrombin leading to


Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
The pharmacology and effectiveness of the oral activated factor X inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran are reviewed.
Inhibition of Factor XIa as a New Approach to Anticoagulation
Data from genetic models and studies using neutralizing antibodies, peptide inhibitors, and small-molecule inhibitors strongly support FXIa inhibition as a viable method to increase the ratio of benefit to risk in an antithrombotic drug.
Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
These findings demonstrate the superior anticoagulant efficacy and rapid avidin neutralizability of EP217609 compared with antICOagulants that target thrombin or factor Xa alone.
Structure-based design of novel potent nonpeptide thrombin inhibitors.
A new structural class of nonpeptidic inhibitors employing a 1,2,5-trisubstituted benzimidazole as the central scaffold is designed and the double-prodrug 31, which showed strong oral activity in different animal species, was chosen for clinical development.
A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits
It is demonstrated that BMS-262084 prevented experimental thrombosis at doses with low BT effects in rabbits, and suggests that a small molecule FXIa inhibitor may represent a promising antithrombotic therapy.
In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.
The rapid onset of action and short half-life in vivo suggest that the thrombin aptamer may be useful in anticoagulation with extracorporeal circuits and may have distinct advantages in certain acute clinical settings.
New Synthetic Thrombin Inhibitors: Molecular Design and Experimental Verification
The high efficacy, stability and low acute toxicity reveal that the inhibitors that were developed may be promising for potential medical applications.
Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo
FM19, a low affinity reversible direct thrombin inhibitor, might be useful as an add‐on agent to address an unmet need in platelet inhibition in acute coronary syndromes in diabetics and others who with all current antiplatelet therapy still have reactive platelets.
Factor IXa inhibitors as novel anticoagulants.
This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.
A Novel Allosteric Pathway of Thrombin Inhibition
Overall, designed sulfated DHPs appear to be the first molecules that bind primarily in the region defined by exosite II and allosterically induce thrombin inhibition and thus represent a novel class of potent dualThrombin and factor Xa inhibitors.